文献速递眼底病与葡萄膜炎

房水蛋白质组学揭示nAMD与pmCNV治疗反应差异的分子基础

Aqueous Humor Proteomics Reveals the Molecular Basis for Differential Treatment Responses in nAMD and pmCNV.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究比较了新生血管性年龄相关性黄斑变性(nAMD)与病理性近视相关脉络膜新生血管(pmCNV)的房水蛋白质组,发现两者蛋白质改变弱相关(r2=0.061),分别具有独特的分子特征。基于33种蛋白质的LightGBM模型实现了0.92的宏平均AUC,SHAP分析突出VEGFR2和VEGFA为nAMD相关驱动因子,Olink验证显示6种选定蛋白质表达趋势一致。

要点

  • nAMD与pmCNV房水蛋白质组改变弱相关,分别有385和398种特异性改变蛋白。
  • nAMD以VEGF/VEGFR通路激活和糖代谢蛋白减少为特征。
  • pmCNV表现为细胞外基质重塑、血小板/凝血激活及Slit/Robo通路下调。

核心结论

  • nAMD与pmCNV具有 largely 不同的房水蛋白质组特征,支持CNV形成和抗VEGF反应性的不同分子机制。
  • 房水蛋白质组学可能有助于优先筛选亚型特异性候选生物标志物,需在独立队列中进一步验证。

研究设计与样本

  • 研究纳入nAMD、pmCNV、年龄相关性白内障对照及无CNV的病理性近视眼房水样本。
  • 采用非标记数据非依赖采集(DIA)质谱进行蛋白质组分析,并用limma模型校正年龄、性别和眼轴长度。

主要发现

  • DIA蛋白质组学鉴定3986种蛋白质,其中3667种通过质量过滤。
  • nAMD与pmCNV蛋白质组改变弱相关(r2=0.061),有385种nAMD特异性、398种pmCNV特异性及100种共享改变蛋白。
  • nAMD特征为VEGF/VEGFR通路激活和葡萄糖代谢相关蛋白减少。
  • pmCNV显示细胞外基质重塑、血小板/凝血激活及Slit/Robo相关神经血管导向通路下调。
  • 基于33种蛋白质的稳定性选择LightGBM模型宏平均AUC为0.92,SHAP分析突出VEGFR2(KDR)和VEGFA为nAMD主要驱动因子。

关键数值与推荐

  • nAMD与pmCNV蛋白质组改变弱相关(r2=0.061)。
  • 基于33种蛋白质的LightGBM模型宏平均AUC为0.92。
  • Olink验证显示6种选定蛋白质表达趋势一致。

临床怎么用

  • 房水蛋白质组学可帮助区分nAMD与pmCNV的分子亚型,为个体化抗VEGF治疗策略提供依据。
  • VEGFR2和VEGFA可作为nAMD相关候选生物标志物,但需进一步临床验证。

局限性

  • 研究结果需在独立队列中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Choroidal neovascularization (CNV) causes vision loss in neovascular age-related macular degeneration (nAMD) and pathologic myopia-related CNV (pmCNV). Despite shared clinical features, they respond differently to treatment. This study compared aqueous humor (AH) proteomic profiles of nAMD and pmCNV to identify biomarkers and mechanisms of CNV formation. METHODS: AH samples were collected from eyes with nAMD, pmCNV, age-related cataract controls, and pathologic myopia without CNV. Label-free data-independent acquisition (DIA) mass spectrometry was used for proteomic profiling. Differentially expressed proteins were identified using limma models adjusted for age, sex, and axial length. Functional enrichment analyses used Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome databases. Stability-based feature selection, LightGBM modeling, and SHapley Additive exPlanations (SHAP) prioritized discriminative proteins; selected findings were evaluated in an independent nAMD-control Olink cohort. RESULTS: DIA proteomics identified 3986 proteins, of which 3667 passed quality filtering. nAMD and pmCNV showed weakly correlated proteomic alterations (r2 = 0.061), with 385 nAMD-specific, 398 pmCNV-specific, and 100 shared altered proteins. nAMD was characterized by vascular endothelial growth factor (VEGF/VEGF receptor [VEGFR]) pathway activation and reduced glucose-metabolism-related proteins, whereas pmCNV showed extracellular matrix remodeling, platelet/coagulation activation, and downregulation of Slit/Robo-related neurovascular guidance pathways. The stability-selected LightGBM model using 33 proteins achieved a macro-average area under the curve (AUC) of 0.92. SHAP analysis highlighted VEGFR2 (KDR) and VEGFA as major nAMD-associated drivers, and Olink validation showed concordant expression trends for six selected proteins. CONCLUSIONS: nAMD and pmCNV exhibit largely distinct AH proteomic signatures, supporting different molecular mechanisms of CNV formation and anti-VEGF responsiveness. AH proteomics may help prioritize subtype-specific candidate biomarkers, warranting further validation across independent cohorts.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhao H, Gao B, Ding N, et al. Aqueous Humor Proteomics Reveals the Molecular Basis for Differential Treatment Responses in nAMD and pmCNV. Invest Ophthalmol Vis Sci. 2026. PMID: 42599028. doi:10.1167/iovs.67.10.36

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。